Your browser doesn't support javascript.
loading
Clonal fitness inferred from time-series modelling of single-cell cancer genomes.
Salehi, Sohrab; Kabeer, Farhia; Ceglia, Nicholas; Andronescu, Mirela; Williams, Marc J; Campbell, Kieran R; Masud, Tehmina; Wang, Beixi; Biele, Justina; Brimhall, Jazmine; Gee, David; Lee, Hakwoo; Ting, Jerome; Zhang, Allen W; Tran, Hoa; O'Flanagan, Ciara; Dorri, Fatemeh; Rusk, Nicole; de Algara, Teresa Ruiz; Lee, So Ra; Cheng, Brian Yu Chieh; Eirew, Peter; Kono, Takako; Pham, Jenifer; Grewal, Diljot; Lai, Daniel; Moore, Richard; Mungall, Andrew J; Marra, Marco A; McPherson, Andrew; Bouchard-Côté, Alexandre; Aparicio, Samuel; Shah, Sohrab P.
Afiliação
  • Salehi S; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Kabeer F; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Ceglia N; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Andronescu M; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Williams MJ; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Campbell KR; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Masud T; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Wang B; Lunenfeld-Tanenbaum Research Institute Mount Sinai Hospital Joseph & Wolf Lebovic Health Complex, Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Biele J; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Brimhall J; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Gee D; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Lee H; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Ting J; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Zhang AW; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Tran H; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • O'Flanagan C; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Dorri F; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Rusk N; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • de Algara TR; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Lee SR; Department of Computer Science, University of British Columbia, Vancouver, British Columbia, Canada.
  • Cheng BYC; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Eirew P; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Kono T; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Pham J; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Grewal D; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Lai D; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Moore R; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Mungall AJ; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Marra MA; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • McPherson A; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.
  • Bouchard-Côté A; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.
  • Shah SP; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nature ; 595(7868): 585-590, 2021 07.
Article em En | MEDLINE | ID: mdl-34163070
ABSTRACT
Progress in defining genomic fitness landscapes in cancer, especially those defined by copy number alterations (CNAs), has been impeded by lack of time-series single-cell sampling of polyclonal populations and temporal statistical models1-7. Here we generated 42,000 genomes from multi-year time-series single-cell whole-genome sequencing of breast epithelium and primary triple-negative breast cancer (TNBC) patient-derived xenografts (PDXs), revealing the nature of CNA-defined clonal fitness dynamics induced by TP53 mutation and cisplatin chemotherapy. Using a new Wright-Fisher population genetics model8,9 to infer clonal fitness, we found that TP53 mutation alters the fitness landscape, reproducibly distributing fitness over a larger number of clones associated with distinct CNAs. Furthermore, in TNBC PDX models with mutated TP53, inferred fitness coefficients from CNA-based genotypes accurately forecast experimentally enforced clonal competition dynamics. Drug treatment in three long-term serially passaged TNBC PDXs resulted in cisplatin-resistant clones emerging from low-fitness phylogenetic lineages in the untreated setting. Conversely, high-fitness clones from treatment-naive controls were eradicated, signalling an inversion of the fitness landscape. Finally, upon release of drug, selection pressure dynamics were reversed, indicating a fitness cost of treatment resistance. Together, our findings define clonal fitness linked to both CNA and therapeutic resistance in polyclonal tumours.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistencia a Medicamentos Antineoplásicos / Variações do Número de Cópias de DNA / Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistencia a Medicamentos Antineoplásicos / Variações do Número de Cópias de DNA / Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article